{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T02:26:25Z","timestamp":1770431185477,"version":"3.49.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.sleep.2006.06.003","type":"journal-article","created":{"date-parts":[[2007,2,3]],"date-time":"2007-02-03T02:46:00Z","timestamp":1170470760000},"page":"181-183","source":"Crossref","is-referenced-by-count":23,"title":["Restless legs syndrome in narcolepsy: A side effect of sodium oxybate?"],"prefix":"10.1016","volume":"8","author":[{"given":"Beatriz","family":"Abril","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Carlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Touchon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Dauvilliers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2006.06.003_bib1","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/S1388-2457(03)00203-7","article-title":"Clinical aspects and pathophysiology of narcolepsy","volume":"114","author":"Dauvilliers","year":"2003","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.sleep.2006.06.003_bib2","unstructured":"U.S. Xyrem\u00ae Multicenter Study group. A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42\u20139."},{"key":"10.1016\/j.sleep.2006.06.003_bib3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/0006-8993(80)90368-6","article-title":"Gamma-hydroxybutyrate: a role in the regulation of central dopaminergic neurons?","volume":"189","author":"Roth","year":"1980","journal-title":"Brain Res"},{"key":"10.1016\/j.sleep.2006.06.003_bib4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ana.10696","article-title":"GABA, gamma-hydroxybutyric acid, and neurological disease","volume":"54","author":"Wong","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2006.06.003_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0301-0082(96)00064-0","article-title":"The gamma-hydroxybutyrate signalling system in brain: organization and functional implications","volume":"51","author":"Maitre","year":"1997","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.sleep.2006.06.003_bib6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ana.410130306","article-title":"Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomnia","volume":"13","author":"Faull","year":"1983","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2006.06.003_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.mp.4000911","article-title":"MAO-A and COMT polymorphisms and gene effects in narcolepsy","volume":"6","author":"Dauvilliers","year":"2001","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.sleep.2006.06.003_bib8","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/01.WNL.0000069608.84542.46","article-title":"Alteration of the striatal dopaminergic system in human narcolepsy","volume":"60","author":"Eisensehr","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2006.06.003_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pneurobio.2005.10.007","article-title":"The restless legs syndrome","volume":"77","author":"Barri\u00e8re","year":"2005","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.sleep.2006.06.003_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.sleep.2004.01.016","article-title":"Parkinson\u2019s disease and RLS: the dopaminergic bridge","volume":"5","author":"Rye","year":"2004","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2006.06.003_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00002826-198902000-00004","article-title":"Nocturnal \u03b3-hydroxybutyrate. Effect on periodic leg movements and sleep organization of narcoleptic patients","volume":"12","author":"B\u00e9dard","year":"1989","journal-title":"Clin Neuropharmacol"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945706001882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945706001882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T09:21:40Z","timestamp":1547025700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945706001882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S1389945706001882"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2006.06.003","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}